1.270USD-1.55%Mkt Cap: 86.66M USDP/E: —Last update: 2026-06-01
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap86.66M USD
Enterprise Value84.05M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.41M USD
Revenue/Share—
Last Price1.270 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.64
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B7.56
EPS (TTM)-0.29
EPS (Forward)-0.28
52W Range
1.05011% of range3.100
52W High3.100 USD
52W Low1.050 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-176.10%
ROA-141.84%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.69M USD
CapEx (TTM)—
FCF Margin—
FCF Yield0.21%
Net Debt-5.36M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity4.09
Current Ratio7.00
Quick Ratio6.72
Book Value/Sh0.1720 USD
Cash/Share0.0810 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.68.77M
Float38.06M
Insiders35.10%
Institutions3.26%
Short Interest
Short Ratio4.8d
Short % Float1.89%
Short % Out.1.52%
Shares Short1.04M
Short (prev mo.)1.04M
Technical
SMA 501.315 (-3.5%)
SMA 2001.361 (-6.7%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)187.58K
Avg Vol (10d)86.97K
Technical Indicators
RSI (14)48.8
MACD-0.0149
MACD Signal-0.0169
MACD Hist.+0.0020
BB Upper1.379 USD
BB Middle1.288 USD
BB Lower1.197 USD
BB Width14.20%
ATR (14)0.0753 USD
Vol Ratio (20d)0.53x